PMID: 6110088Feb 28, 1981Paper

Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff

Lancet
J CrosnierP Guesry

Abstract

A vaccine against hepatitis B surface antigen (Institut Pasteur Production) was assessed in staff members from forty-eight French haemodialysis units where the risk of hepatitis B was high. Of 318 subjects who completed the protocol, 164 received three monthly injections of vaccine and 154 received corresponding injections of placebo. Hepatitis B infection was observed in 3.6% of the vaccine group and 12.3% of the placebo group (p less than 0.005). The 6 infections in the vaccine group all arose within 63 days from the first injections, whereas the 19 in the placebo group arose throughout the 12 months of follow-up. The rate of side-effects after injection did not differ in the two groups. 94% of the vaccine recipients had an immune response ( greater than 10 mIU/ml in at least 5 successive specimens). 4 months after the first injection the mean + or - 2 SE peak level of anti-HBs was 2433 + or - 1077 mIU/ml.

Citations

Nov 1, 1990·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·G PillionC Loirat
Aug 1, 1992·Digestive Diseases and Sciences·D H Van ThielT E Starzl
Jun 27, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Mukta MantanGulshan Rai Sethi
Oct 20, 2001·Science and Engineering Ethics·Tom Jefferson
Sep 4, 1989·The American Journal of Medicine·F E André
Jul 1, 1986·Journal of Biological Standardization·W Frisch-NiggemeyerH Hofmann
May 18, 1991·Lancet·P CoursagetI Diop-Mar
Apr 1, 1985·Journal of Virological Methods·R A HeijtinkN Masurel
Jan 1, 1993·Vaccine·A R ZanettiI Grappasonni
Jul 1, 1985·Journal of Biological Standardization·M C MazertA Goudeau
Oct 13, 1984·Lancet·A LaplancheJ Crosnier
Nov 24, 1984·Lancet·W JilgF Deinhardt
Nov 9, 1985·Lancet·R S SaddiN Thibult
Dec 12, 1987·Lancet·P CoursagetJ P Chiron
May 23, 1987·Lancet·A LaplancheP Jungers
Jun 10, 1982·The New England Journal of Medicine·C BréchotP Berthelot
Dec 9, 1982·The New England Journal of Medicine·W SzmunessA Kellner
Aug 23, 1984·The New England Journal of Medicine·C E StevensW Szmuness
Dec 6, 1984·The New England Journal of Medicine·A M CourouceJ Crosnier
Jul 24, 1986·The New England Journal of Medicine·S C HadlerN L Altman
Jan 1, 1984·Biotechnology & Genetic Engineering Reviews·G L SmithB Moss
Apr 25, 2013·Journal of Biopharmaceutical Statistics·Shu LiIvan S F Chan
Jul 1, 1989·Journal of Gastroenterology and Hepatology·J Y LauH J Lin
Jan 17, 2004·Lancet·Vasee S MoorthyAdrian V S Hill
Jun 23, 2015·Expert Opinion on Biological Therapy·Roberto Camerini, Enrico Garaci
Mar 1, 1985·Acta paediatrica Scandinavica·L M CallisR Lardinois
Sep 1, 1981·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W SzmunessA Kellner
Jan 1, 1982·Journal of Medical Virology·G J PapaevangelouS Krugman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.